24623-40-3

Usage

Uses

Used in Organic Synthesis:
1,3-Dichloro-7-methoxyisoquinoline is used as a building block in organic synthesis for its ability to contribute to the formation of various pharmaceuticals and organic compounds, enhancing the diversity and complexity of synthesized products.
Used in Pharmaceutical Research:
In pharmaceutical research, 1,3-Dichloro-7-methoxyisoquinoline is utilized as a starting material for the synthesis of heterocyclic compounds, which are essential in the development of new drugs and medicinal agents.
Used in Medicinal Chemistry and Drug Discovery:
1,3-Dichloro-7-methoxyisoquinoline is employed as a valuable tool in medicinal chemistry and drug discovery, where its unique structure and properties aid researchers in exploring its potential biological activities and pharmacological effects.
Used in the Study of Biological Activities:
1,3-Dichloro-7-methoxyisoquinoline has been studied for its potential biological activities, indicating its interest for researchers in the field of pharmacology who are looking into its possible therapeutic applications and effects.

Upstream product

• 24077-98-3 (Z)-2-(hydroxyimino)-6-methoxy-2,3-dihydro-1H-inden-1-one 
• 13623-25-1 6-methoxy-2,3-dihydro-1H-inden-1-one 
• 24077-98-3 2-(hydroxyimino)-6-methoxy-2,3-dihydro-1H-inden-1-one 

Downstream Products

• 1383379-89-2 3-fluoro-4-(7-methoxyisoquinolin-3-yl)benzoic acid 
• 82117-21-3 3-chloro-7-methoxyisoquinoline 
• 1383379-67-6 3-fluoro-4-(7-hydroxyisoquinolin-3-yl)benzoic acid 
• 1383379-90-5 4-(7-methoxy-4-methylisoquinolin-3-yl)benzoic acid 
• 1383379-68-7 4-(7-hydroxy-4-methylisoquinolin-3-yl)benzoic acid 
• 82117-25-7 3-chloroisoquinolin-7-ol 

Relevant academic research and scientific papers

AMINOISOXAZOLINE COMPOUNDS AS AGONISTS OF ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTORS

The present invention relates to novel aminoisoxazoline compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of α7-nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

BICYCLIC ARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS

The present invention relates to bicyclic aryl monobactam compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein A1, L, M, W, X, Y, Z, RX and Rz are as defined herein. The present invention also relates to compositions which comprise a bicyclic aryl monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of one or more beta-lactamase inhibitor compounds.

PYRROLO[2,3-C]PYRIDINES AS IMAGING AGENTS FOR NEUROFIBRILARY TANGLES

Pyrrolopyridine compounds of formula (I) or their pharmaceutically acceptable salts are disclosed, which may be suitable for imaging tau aggregates, b-sheet aggregates, beta-amyloid aggregates or alpha- synuclein aggregates, and hence are useful in binding and imaging tau aggregates in Alzheimer's patients. More specifically, the compounds are used as tracers in positron emission tomography (PET) imaging to study tau deposits in brain in vivo to allow diagnosis of Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology. Futher, the compounds are useful for measuring clinical efficacy of therapeutic agents for Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology.

NOVEL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS

The present invention is directed to novel substituted bicyclic aromatic compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.